MultiCell Technologies (MCET) Stock Message Board

Moderator: dr_lowenstein, sup105, LuckyDefender, downandoutthanksd

Search This Board:

Last Post: 3/1/2021 9:39:15 AM - Followers: 616 - Board type: Free - Posts Today: 3

MultiCell Technologies, Inc., a Delaware corporation was incorporated on April 28, 1970. It is a biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. The Company operates two subsidiaries, Xenogenics Corporation and MultiCell Immunotherapeutics, Inc. Its therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company's portfolio of drug candidates in various stages of discovery optimization and preclinical and clinical development are: MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138-patient Phase IIa clinical trial; MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3, MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers. Many of the Company's competitors have greater financial, manufacturing, marketing and drug development resources than it does. It faces competition from pharmaceutical companies as well as biotechnology companies that are also researching and selling products similar to the Company. The research, testing, manufacturing, selling and marketing of drug candidates are subject to regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country.

GOVERNMENT GRANTS: Product Details Fa2N-4 Line Price and LICENSE AGREEMENT:

Immortalized Human Hepatocyte Cell Lines
(MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA).

IFH15 = $425.00 Dollar

Cryopreserved Fa2N-4 Line – Immortalized Hepatocytes
Cryopreserved cells, 1.5 mL vial
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Unit of Measure: 1.5mL
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifh15/

IFHP.06 = $672.00 Dollar

Fa2N-4 Line – 6 well – Collagen Coated Plate
Plated cells, 6-well plate
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifhp-06/

IFHP.12 = $672.00 Dollar

Fa2N-4 Line – 12 well – Collagen Coated Plate
Plated cells, 12-well plate
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifhp-12/

IFHP.24 = $672.00 Dollar

Fa2N-4 Line – 24 well – Collagen Coated Plate

Plated cells, 24-well plates
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifhp-24/

IFHP.48 = $672.00 Dollar

Fa2N-4 Line – 48 well – Collagen Coated Plate

Plated cells, 48-well plates
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifhp-48/

IFHP.96 = $672.00 Doller

Fa2N-4 Line – 96 well – Collagen Coated Plate
Plated cells, 96-well plates
Category: Cryopreserved Hepatocytes (Single Donor)
Species: Human
Gender: N/A
Our optimized media is strongly recommended to be able to reproduce the results shown on the datasheets below.
https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/ifhp-96/

License Agreement https://www.realdealdocs.com/viewdocument.aspx?DocumentID=14890

3.Payments.

3.1 License Fees. XENOTECH has made, and will make, the following license fee payments to MULTICELL in the following manner:

3.1.1 At the signing of the existing Letter of Intent between XENOTECH and MULTICELL on July 8, 2003, XENOTECH paid MULTICELL the sum of fifty thousand dollars ($50,000), as a portion of the "Prepaid Royalties", for an exclusive worldwide license during the Term (unless earlier terminated along with license to Cell Lines as provided herein) in the MFE Formula;

3.1.2 At the Closing, XENOTECH shall pay to MULTICELL the sum of one hundred fifty thousand dollars ($150,000) (the "Closing Payment"), said Closing Payment being a portion of the "Prepaid Royalties" and place a non-refundable eight hundred thousand dollar ($800,000) payment (the "Relocation Payment") into a mutually agreeable escrow account;

3.1.3 Within three (3) business days after the Relocation, XENOTECH shall instruct the escrow agent to release to MULTICELL the non-refundable Relocation Payment from escrow. Once released, the Relocation Payment shall be consideration for, and a guarantee of, Nosan's right of first negotiation for distribution rights for the Asian Pacific Rim as provided in Section 12.3 herein; and

3.1.4 Within ten (10) days after the Cell Line Training, XENOTECH shall pay MULTICELL the sum of five hundred thousand dollars ($500,000) (the "Training Payment"). Once paid, the Training Payment shall be considered a portion of the "Prepaid Royalties".

3.2 Running Royalty Payments. XENOTECH shall pay MULTICELL (in accordance with Article 7 herein) ongoing royalty payments (hereinafter "Running Royalties") throughout the Term on Net Sales of Licensed Products and Licensed Services Sold by XENOTECH or its Affiliates, and on sublicenses and other agreements with third parties, as follows:

3.2.1 thirty four percent (34%) of Net Sales for use and/or propagation sublicenses of Cell Lines or Cell Line Improvements to clients or third parties of XENOTECH;

3.2.2 seventeen and one-half percent (17.5%) of Net Sales of Cell Lines or Cell Line Improvements to third parties;

3.2.3 two and one-half percent (2.5%) of Net Sales of in-house studies, using Cell Lines or Cell Line Improvements, for the benefit of XENOTECH'S clients and/or third parties;

3.2.4 ten percent (10%) of Net Sales of MFE media, and Permitted Improvements to the MFE, to third parties;

3.2.5 ten percent (10%) of Net Sales of in-house studies, using Cell Lines or Cell Line Improvements in studies of a type not currently performed by XENOTECH and which type of study is enabled because of the Cell Lines and/or Cell Line Improvements; and

3.2.6 fifteen percent (15%) of Net Sales for any other sale, sublicense, transfer or other permitted use of the MULTICELL Technology and Permitted Improvements, other than as provided in paragraph 3.2.1 through 3.2.5 herein. Running Royalty payments will be made within forty-five (45) calendar days of the close of each calendar quarter.

3.3 Running Royalty Credits. The actual amount paid pursuant to Section 3.2 above, shall be determined by the total Running Royalties for a given quarter, less a credit from the Prepaid Royalties, until such credit is exhausted, as follows. The maximum credit that XENOTECH shall be entitled to offset against Running Royalties is $700,000 from the Prepaid Royalties ("Maximum Credit"). The Relocation Payment is nonrefundable and non-creditable without offset of any kind . When Running Royalties are due from XENOTECH to MULTICELL, XENOTECH will pay twenty five percent (25%) of the amount due in said quarter in cash to MULTICELL and can offset the remaining seventy five percent (75%) due MULTICELL against the Maximum Credit. XENOTECH can continue to utilize the remaining portion of the Maximum Credit in subsequent quarters, continuing at the rate of seventy five percent (75%) of the amount due, until it is fully exhausted. Thereafter, XENOTECH shall pay the full amount (100%) of the Running Royalties in each quarter in cash without any further credits or offsets due or applicable from License Fees paid pursuant to Section 3.1.

3.4 Running Royalty Adjustments. The Running Royalty rates of 3.2.1 to 3.2.6 provided above shall be adjusted in the following situations: (i) for Permitted Joint Improvements, the Running Royalty rates payable by XENOTECH shall be reduced to seventy five percent (75%) of the rates shown therein and (ii) for permitted XENOTECH Improvements, the Running Royalty rates payable by XENOTECH shall be reduced to fifty percent (50%) of the rates shown therein.

3.5 Guaranteed Minimum Running Royalties. In order for XENOTECH to maintain its exclusive license and right under this Agreement, XENOTECH shall pay to MULTICELL guaranteed minimum Running Royalties ("Minimum Running Royalties"), inclusive of any credits from the Maximum Credit, as follows:

Time Period Minimum

First 16 months from the Effective Date: $ 800,000
Months 17 through 28 from the Effective Date: $ 2,100,000
Months 29 through 40 from the Effective Date: $ 2,600,000
Months 41 through 52 from the Effective Date: $ 3,000,000
Months 53 through 64 from the Effective Date: $ 3,300,000
Months 65 through 76 from the Effective Date: $ 3,630,000
Months 77 through 84 from the Effective Date: $ 2,662,000

If, in any Time Period listed above, the actual Running Royalties exceed the noted Minimum Running Royalties for that Time Period, then XENOTECH shall be entitled to credit that excess amount towards any shortfall in next Time Period, but only to the extent that the actual Running Royalties payable in said next Time Period fall short of the guaranteed Minimum Running Royalties for that Time Period. In the event that XENOTECH fails to meet the guaranteed Minimum Running Royalties for any Time Period, then MULTICELL shall be entitled to credit the shortfall against the remaining Maximum Credits due XENOTECH, if any, provided, however, such credits shall not exceed the Maximum Credit. In the event that XENOTECH fails to pay or have credited (against the Maximum Credit) at least twenty five percent (25%) of the Minimum Running Royalties for any Time Period provided above, then MULTICELL shall have sixty (60) days, at its option, to notify XENOTECH that any and all of XENOTECH'S license and rights under this Agreement are terminated in accordance with Article 9 herein. Upon said termination, XENOTECH shall, within thirty (30) days, return all MultiCell Technologies, information, assets and other materials to MULTICELL, including any and all Improvements, to sell any remaining inventory, subject to the payment obligations to MULTICELL noted herein, to cease any all further sales of Cell Lines, Cell Line Improvements, MFE or its Permitted Improvements, and to execute all instruments reasonably necessary, if any, to re-vest said license and rights solely in MULTICELL. XENOTECH s

https://www.marketwatch.com/investing/stock/mcet/analystestimates?mod=mw_quote_analyst
https://money.cnn.com/quote/forecast/forecast.html?symb=MCET

Bio Med Central Article (PB)
https://www.biomedcentral.com/search?query=MCET&searchType=publisherSearch

MCET
Current Price
Volume:

Bid	Ask	Day's Range


MCET Detailed Quote

MultiCell Technologies (MCET)

About

Help

Educational

More